Request that the FDA declare that Clemastine Fumarate Tablets, 1.34 mg and 0.67 mg, are suitable for submission as an ANDA for prescription use
🏛 Food and Drug Administration (FDA)FDA-2025-P-6088
Documents
0
Total comments
0
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
No documents mirrored for this docket yet.